Big Money Are Crazy About Cleveland Biolabs Inc (NASDAQ:CBLI), Sentiment at 1

May 16, 2018 - By Darrel Chase

Cleveland BioLabs, Inc. (NASDAQ:CBLI) Corporate Logo

Positions for Cleveland Biolabs Inc (NASDAQ:CBLI)

“Big money sentiment for Cleveland Biolabs Inc (NASDAQ:CBLI) in Q4 2017 decreased to 1, according to Securities and Exchange Commission filings. That’s down -0.50, from 2017Q3’s 1.5. 5 active investment managers increased or started new stock positions, while 5 sold and decreased their stock positions in Cleveland Biolabs Inc so the sentiment turned negative. These funds own 441,233 shares, that’s up from 438,124 shares in 2017Q3. Funds holding Cleveland Biolabs Inc in top 10 changed to 0 from 0 for the same number . 2 Investors Sold All; 3 Reduced Holdings; 2 increased stakes while 3 active investment managers bought stakes.

Most Cleveland Biolabs Inc Investors

As of Q4 2017 Bank Of America Corp De has 0% invested in Cleveland Biolabs Inc. Cleveland Biolabs Inc’s shareholder Bank Of Montreal Can owns 31 shares as of Q4 2017. Furthermore, Blackrock Inc. reported 14,732 shares in Cleveland Biolabs Inc equivalent to 0% of its stocks portfolio. The Germany-based fund Deutsche Bank Ag have invested about 0% of the institutional investor’s stock portfolio in Cleveland Biolabs Inc. The Massachusetts-based fund Geode Capital Management Llc holds 16,688 shares or 0% of their stocks portfolio.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation.The firm is worth $31.36 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug.Currently it has negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

Lastly it traded at $2.78.Since May 16, 2017 it’s 101.92% down thus uptrending. CBLI outperformed the S&P 500 by 90.37%.

Wells Fargo & Mn holds 150 shs or 0% of its capital. Winfield Assocs holds 0% or 500 shs in its capital. Stratos Wealth Prtnrs Ltd stated it has 0% of its capital in Cleveland BioLabs, Inc. (NASDAQ:CBLI). 16,688 were accumulated by Geode Capital Mgmt Ltd Llc. Renaissance Technology Limited Liability, New York-based fund reported 241,016 shs. Moreover, Deutsche Commercial Bank Ag has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 4 shs. Blackrock reported 14,732 shs stake. Us Savings Bank De holds 100 shs. Moreover, Gp One Trading L P has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 68 shs. Vanguard has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI). State Bank Of America De has 100 shs for 0% of their capital. Panagora Asset Mngmt owns 10,427 shs. Natl Bank Of Montreal Can reported 31 shs stake. Morgan Stanley stated it has 50 shs or 0% of all its holdings. 1 are held by Royal Bancorp Of Canada.

There’s an important Cleveland BioLabs, Inc. (NASDAQ:CBLI) news announced by Digitaljournal.com. It’s a report titled: “Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress” on May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.